BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21317922)

  • 21. Targeting B7‑H3 through EZH2 inhibition in MYC‑positive Group 3 medulloblastoma.
    Shishido K; Purvis IJ; Velpula KK; Venkataraman S; Vibhakar R; Asuthkar S
    Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37114557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
    Bolin S; Borgenvik A; Persson CU; Sundström A; Qi J; Bradner JE; Weiss WA; Cho YJ; Weishaupt H; Swartling FJ
    Oncogene; 2018 May; 37(21):2850-2862. PubMed ID: 29511348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
    Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
    Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 MYC-amplified Medulloblastoma.
    Coulter DW; Chhonker YS; Kumar D; Kesherwani V; Aldhafiri WN; McIntyre EM; Alexander G; Ray S; Joshi SS; Li R; Murry DJ; Chaturvedi NK
    J Exp Clin Cancer Res; 2024 Jan; 43(1):18. PubMed ID: 38200580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple genomic alterations including N-myc amplification in a primary large cell medulloblastoma.
    Reardon DA; Jenkins JJ; Sublett JE; Burger PC; Kun LK
    Pediatr Neurosurg; 2000 Apr; 32(4):187-91. PubMed ID: 10940769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-222-3p inhibits formation of medulloblastoma stem-like cells by targeting Notch2/c-myc signaling pathway.
    Wang H; Wang Y; Wang Y
    Immunopharmacol Immunotoxicol; 2022 Aug; 44(4):548-555. PubMed ID: 35379056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth.
    Hatton BA; Knoepfler PS; Kenney AM; Rowitch DH; de Alborán IM; Olson JM; Eisenman RN
    Cancer Res; 2006 Sep; 66(17):8655-61. PubMed ID: 16951180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation.
    Su X; Gopalakrishnan V; Stearns D; Aldape K; Lang FF; Fuller G; Snyder E; Eberhart CG; Majumder S
    Mol Cell Biol; 2006 Mar; 26(5):1666-78. PubMed ID: 16478988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling medulloblastoma in vivo and with human cerebellar organoids.
    Ballabio C; Anderle M; Gianesello M; Lago C; Miele E; Cardano M; Aiello G; Piazza S; Caron D; Gianno F; Ciolfi A; Pedace L; Mastronuzzi A; Tartaglia M; Locatelli F; Ferretti E; Giangaspero F; Tiberi L
    Nat Commun; 2020 Jan; 11(1):583. PubMed ID: 31996670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.
    Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y
    J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells.
    Vollmer J; Ecker J; Hielscher T; Valinciute G; Ridinger J; Jamaladdin N; Peterziel H; van Tilburg CM; Oehme I; Witt O; Milde T
    J Neurooncol; 2023 Sep; 164(3):617-632. PubMed ID: 37783879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene amplification in PNETs/medulloblastomas: mapping of a novel amplified gene within the MYCN amplicon.
    Frühwald MC; O'Dorisio MS; Rush LJ; Reiter JL; Smiraglia DJ; Wenger G; Costello JF; White PS; Krahe R; Brodeur GM; Plass C
    J Med Genet; 2000 Jul; 37(7):501-9. PubMed ID: 10882752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional analysis of HOXA10 and HOXB4 in human medulloblastoma cell lines.
    Bonfim-Silva R; Ferreira Melo FU; Thomé CH; Abraham KJ; De Souza FAL; Ramalho FS; Machado HR; De Oliveira RS; Cardoso AA; Covas DT; Fontes AM
    Int J Oncol; 2017 Dec; 51(6):1929-1940. PubMed ID: 29039487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma.
    Wang F; Remke M; Bhat K; Wong ET; Zhou S; Ramaswamy V; Dubuc A; Fonkem E; Salem S; Zhang H; Hsieh TC; O'Rourke ST; Wu L; Li DW; Hawkins C; Kohane IS; Wu JM; Wu M; Taylor MD; Wu E
    Oncotarget; 2015 Feb; 6(5):2709-24. PubMed ID: 25576913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma.
    Zitterbart K; Filkova H; Tomasikova L; Necesalova E; Zambo I; Kantorova D; Slamova I; Vranova V; Zezulkova D; Pesakova M; Pavelka Z; Veselska R; Kuglik P; Sterba J
    J Neurooncol; 2011 Mar; 102(1):25-33. PubMed ID: 20607354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.
    Xu Z; Murad N; Malawsky D; Tao R; Rivero-Hinojosa S; Holdhof D; Schüller U; Zhang P; Lazarski C; Rood BR; Packer R; Gershon T; Pei Y
    Clin Cancer Res; 2022 Oct; 28(19):4278-4291. PubMed ID: 35736214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of genes that are regulated transcriptionally by Myc in childhood tumors.
    Raetz EA; Kim MK; Moos P; Carlson M; Bruggers C; Hooper DK; Foot L; Liu T; Seeger R; Carroll WL
    Cancer; 2003 Aug; 98(4):841-53. PubMed ID: 12910530
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y
    Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Phosphoinositide 3-Kinase p110α Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma.
    Salm F; Dimitrova V; von Bueren AO; Ćwiek P; Rehrauer H; Djonov V; Anderle P; Arcaro A
    PLoS One; 2015; 10(4):e0123958. PubMed ID: 25915540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An animal model of MYC-driven medulloblastoma.
    Pei Y; Moore CE; Wang J; Tewari AK; Eroshkin A; Cho YJ; Witt H; Korshunov A; Read TA; Sun JL; Schmitt EM; Miller CR; Buckley AF; McLendon RE; Westbrook TF; Northcott PA; Taylor MD; Pfister SM; Febbo PG; Wechsler-Reya RJ
    Cancer Cell; 2012 Feb; 21(2):155-67. PubMed ID: 22340590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.